

























Preferred sources	NICE (England and Wales)	SMC (Scotland)	CADTH (Canada)	HAS (France)	PBAC (Australia)
Health state	• EQ-5D ² 	• EQ-5D 	• PBM 	• PBM 	• MAUI 
Valuation	• TTO in UK 	• TTO or SG	• TTO, SG and VAS in Canada 		• TTO or SG in Australia 

Back-up sources	NICE (England and Wales)	SMC (Scotland)	CADTH (Canada)	HAS (France)	PBAC (Australia)
	• EQ-5D-derived HSUV 	• Condition-specific HRQoL to generic PBM 	• SG (preferred), TTO or VAS (but not in isolation)	• EQ-5D or HUI3 to generic PBM	• Post-trial transformation to estimate HSUVs
	• Condition-specific HRQoL to EQ-5D 	• TTO or SG 	• HSUVs 	• TTO or SG	• TTO or SG 
		• HSUVs 		•  Not recommended	• Population matching using a MAUI
		• HSUVs 			• Condition-specific HRQoL to MAUI 
					• HSUVs 

	Patients
	Caregivers/others
	General population
	Published literature
	Mapping function